Officials with Immunovaccine Inc. recently announced that Pulitzer Prize-winning journalist Albert Scardino has joined its board of directors.
Immunovaccine Inc. president and CEO Dr. Randal Chase said he was excited about the appointment.
“We have built strong relationships in the U.K. and are delighted to have Mr. Scardino on our board,” Chase said. “We expect that his business acumen and depth of knowledge in communications will prove invaluable to the board.”
Scardino, a London-based journalist, media investor and communications strategist, has served as a reporter for the New York Timers and as editor for The Guardian. He also formerly served as a press secretary for the mayor of New York and as an advisor for the director of the Securities and Exchange Commission.
Scardino received his bachelor's degree from Columbia University and his master's in journalism from the University of California - Berkeley.
Scardino said that he is pleased with his latest role with Immunovaccine Inc.
“I am honored to serve on the board of Immunovaccine and look forward to bringing broader attention to the remarkable science the company has developed,” Scardino said.
Immunovaccine Inc. is a clinical stage vaccine development company currently at work on the commercialization of its patented DepoVax vaccine delivery technology.